Related Experiment Video
Updated: Sep 10, 2025

06:27
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
562
EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma
Cheyanne C Slocum1, Phuong Nguyen1, Meenakshi Vij1
1Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Acta Neuropathologica
|August 19, 2025
Abstract
No abstract available in PubMed .
Keywords:
EGFR amplificationTERT promoter mutationAstrocytomaCopy number variation (CNV)GlioblastomaHomozygous CDKN2A/B deletionIDH mutationOligodendrogliomaTumor mutation burden (TMB)cIMPACT-NOW+ 7/-10More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K

